On December 12, the IV Real4Reg Consortium Meeting united the project partners for a day filled with in-depth discussions and exchanges focused on the progress of the work packages, addressing primary challenges, brainstorming ideas for overcoming obstacles, and outlining strategic plans for 2024.
The afternoon session had the presence of experts from the Real4Reg Advisory Board and, for the first time, representatives of our sister projects at the MetReal Cluster. A high point of the day was an invited talk by Dr Daniel Morales from the European Medicines Agency on “Federated networks for pharmacoepidemiology studies”, followed by a lively discussion on the topic.
During a breakout session, participants had the chance to actively talk about the current topics, tasks, and potential challenges across the different work packages in the project. One group focused on the use of real-world data (RWD) for control groups and to complement single-arm trials, as well as target trial emulation with RWD.
Another group discussed the development of a training concept regarding the use of real-world evidence in regulatory decision-making processes and health technology assessment. The experiences and ideas shared during these discussions proved to be incredibly valuable for shaping the upcoming activities of Real4Reg.
After the project’s inaugural year, the group looks forward to entering our second year with increased determination and a variety of insights gained from our collaborative efforts.